Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Top Buys by Directors: Costley's $266K Bet on PBH
Tuesday, February 6, 11:26 AM ET, by Market News Video Staff

The directors of a company tend to have a unique inside view into the business, ...

CORT Crosses Below Key Moving Average Level
Thursday, February 8, 12:13 PM ET, by Market News Video Staff

In trading on Thursday, shares of Corcept Therapeutics Inc (CORT) crossed below their 200 day ...

Corcept Therapeutics Becomes Oversold (CORT)
Thursday, February 8, 4:43 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Pacira Pharmaceuticals: A 28.4% Better Bargain Than When Kronenfeld Bought
Friday, February 16, 11:35 AM ET, by Market News Video Staff

There's an old saying on Wall Street about insider buying: there are many possible reasons ...

RSI Alert: Pacira Pharmaceuticals Now Oversold
Friday, February 16, 11:55 AM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

SLXP Crosses Above Key Moving Average Level

By Market News Video Staff, Thursday, June 30, 4:38 PM ET
Play Video: Learn About The 200 DMA

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In trading on Thursday, shares of Salix Pharmaceuticals Ltd (SLXP) crossed above their 200 day moving average of $39.60, changing hands as high as $39.99 per share. Salix Pharmaceuticals Ltd shares are currently trading up about 2.4% on the day. The chart below shows the one year performance of SLXP shares, versus its 200 day moving average:

Salix Pharmaceuticals Ltd 200 Day Moving Average Chart

Looking at the chart above, SLXP's low point in its 52 week range is $31.29 per share, with $49.05 as the 52 week high point that compares with a last trade of $39.83.

According to the ETF Finder at ETF Channel, SLXP makes up 4.23% of the SPDR S&P Pharmaceuticals ETF (NYSE:XPH) which is trading up by about 0.9% on the day Thursday.

See what other ETFs contain SLXP
See what other stocks are held by XPH

SLXP operates in the Drugs & Pharmaceuticals sector, among companies like Alimera Sciences, Inc. (NASDAQ:ALIM) which is off about 1.1% today, and Aegerion Pharmaceuticals Inc (AEGR) trading lower by about 0.2%. Below is a three month price history chart comparing the stock performance of SLXP, versus ALIM and AEGR.

SLXP,ALIM,AEGR Relative Performance Chart


The ETF Channel Flexible Growth Investment Portfolio is designed to seek growth for investors anywhere and everywhere. The key to the program is our portfolio strategy allows us complete flexibility in terms of asset allocation as there are no predetermined guidelines as to the level of stocks, bonds, cash, regions, countries, sectors, commodities, or even asset classes in the portfolio! In short, this is a completely flexible portfolio designed to follow the performance trail wherever it leads us.

This Article's Word Cloud:   AEGR   ALIM   Above   According   Aegerion   Alimera   Average   Below   Channel   Crossing   Drugs   ETFs   Finder   Flexible   Free   Growth   Investment   Looking   Moving   NYSE   Pharmaceuticals   Portfolio   SLXP   SPDR   Salix   Sciences   Start   Stocks   Thursday   about   above   asset   average   chart   designed   high   moving   other   performance   point   portfolio   share   shares   stocks   trading   versus   week   what   which   with
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Portfolio Channel Stock Market Definitions

SLXP Crosses Above Key Moving Average Level | Market News Video | Copyright © 2008 - 2018, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.